Keywords: EMEA, Tysabri, Elan, Biogen, GlaxoSmithKline, Arepanrix, Arzerra, Flu vaccines, Tamiflu
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
Article | 22 January 2010
The European Medicines Agency (EMEA) has finalized a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus, saying the drug continues to outweigh risks for patients with highly active relapsing-remitting multiple sclerosis who have few options for alternative treatment.
T Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.
30 day FREE trial
Sign up in less than 60 seconds! No payment needed.
Want to read the full article?
Take a 30 day FREE Trial
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Transgene signs billion dollar deal with Novartis for TG4010 cancer vaccine option, but still disappoints investors
- US FDA issues complete response on Amgen’s Prolia with July action date
- FDA and European Medicines Agency agree to accept a single orphan drug designation annual report
- Abbott Labs bids $722 for Facet to enhances its biotech R&D pipeline, including daclizumab
- Japanese Pharma market seeing more foreign entrants
